The Pharma Data

DECEMBER 22, 2020

Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1. The company engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed.

Development 52

Development Engineer Manufacturing In-Vitro 52

The Pharma Data

DECEMBER 13, 2020

As part of the collaboration, Hummingbird will be leveraging Tempus’ AI-enabled platform and proprietary data, as well as joining its TIME Trial® Network, for rapid identification, site activation and efficient enrollment of cancer patients who have NRG1 fusions and meet eligibility criteria for HMBD-001 clinical trials.

Clinical Development 40

Clinical Development Medicine Development Antibody 40

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

The Pharma Data

MAY 31, 2022

BIIB122 is an investigational small molecule inhibitor of LRRK2 that was discovered and developed by Denali. Denali and Biogen are co-developing and co-commercializing BIIB122 for the potential treatment of Parkinson’s disease. Senior Vice President, Head of Neurodegeneration Development at Biogen.

Engineer 52

Engineer Development Genetics Clinical Development 52

The Pharma Data

OCTOBER 27, 2020

AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. The company’s lead program is aimed at Friedrich’s Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction.

Gene 52

Gene Gene Therapy Medicine Development 52

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 19, 2021

That is why Arcus and other TIGIT antibody developers like Bristol-Myers Squibb have inactivated the Fc region in an attempt to make their drugs more potent, although the jury is still out about the relative merits of each approach. The post Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs appeared first on.

Drugs 52

Drugs Antibody Development Engineer 52

The Pharma Data

JANUARY 27, 2021

As a clinician, healthcare administrator, biotech entrepreneur and venture capital investor, Steve’s leadership and breadth of experience in the clinical development of cell and gene therapies will be invaluable to PlateletBio as we progress our cell therapy platform into the clinic later this year,” said Sam Rasty, Ph.D.,

Genetic Engineering 40

Genetic Engineering Gene Therapy Gene Engineer 40

XTalks

FEBRUARY 24, 2023

Genentech’s ongoing clinical development program for Lunsumio is evaluating the drug as a monotherapy and in combination with other medicines for the treatment of B-cell NHLs, including FL and diffuse large B-cell lymphoma (DLBCL).

Drugs 52

Drugs FDA Approval Antibody Medicine 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

JANUARY 19, 2021

Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 CAMBRIDGE, Mass., Forward-Looking Statements.

Gene Expression 40

Gene Expression Containment Genetics Clinical Development 40

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.

RNA 52

RNA Antibody Life Science Protein 52

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

The Pharma Data

OCTOBER 26, 2020

These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP). AR-101 (HAP).

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

pharmaphorum

OCTOBER 26, 2022

For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. We design our clinical development strategy and the trials with this aim in mind.”. Caring for a global community.

Development 96

Development Trials Marketing Life Science 96

The Pharma Data

APRIL 27, 2023

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.

Genetic Engineering 40

Genetic Engineering Clinical Development Antibody Medicine 40

The Pharma Data

OCTOBER 19, 2020

“Molecular profiling is a powerful tool that Winship’s physicians can utilize to optimize cancer treatments by accessing relevant genetic information that can have a meaningful impact on patient care at a personalized level.” Brille , Vice Chairman of Caris Life Sciences.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). For additional information, please visit [link].

Licensing 40

Licensing Licensing Dermatology Production 40

Roots Analysis

OCTOBER 30, 2023

The support from venture capitalists and big pharmaceutical companies will continue to drive the development of circular RNA therapeutics and RNA therapeutics market growth over the forecast period. The primary target indications for tRNA therapeutics include genetic and oncological disorders.

RNA 40

RNA Vaccination Vaccine Development 40

Pharmaceutical Technology

AUGUST 17, 2022

These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets. In order to offer complete process development, quality control and regulatory services, cGMP manufacturing for pre-clinical and Phase I/II clinical trials, AGC will use its worldwide network.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

Delveinsight

DECEMBER 8, 2020

KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market.

Licensing 52

Licensing Licensing Gene Therapy Antibody 52

pharmaphorum

JANUARY 4, 2023

Because these products can be efficiently manufactured in large batches, the approach eases some of the challenges associated with autologous cell therapies (in which a patient’ cells are collected, genetically modified, and then returned to the patient) and offers the potential to accelerate time to therapy and broaden access globally.

Gene Therapy 98

Gene Therapy Manufacturing Gene Production 98

Advarra

AUGUST 10, 2023

This will aid clinical development and preparation for investigational new drug (IND) and biologics license application (BLA) submissions. The project should also help clinical research sponsors take advantage of various FDA pathways for accelerated review and approval.

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

Delveinsight

FEBRUARY 12, 2021

Furthermore, GlaxoSmithKline is developing GSK3377794 (NY-ESO-1 T-cells; GSK ‘794), a NY-ESO-1-directed genetically modified autologous T-cell immunotherapy and is an engineered T-cell therapy. What can be expected from ongoing clinical trials in the Synovial sarcoma landscape? million in 2017. Argininosuccinic aciduria.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

The Pharma Data

OCTOBER 27, 2020

Clynes established the critical role of Fc receptor engagement underlying the efficacy of antitumor antibodies, providing the road map for the development of a new class of potency enhanced Fc engineered antibodies in cancer, including anti-CD20, anti-CD19 and anti-HER2 antibodies (obinutuzumab, tafacitamab, margetuximab).

Antibody 40

Antibody Genetic Engineering Engineer Development 40

The Pharma Data

NOVEMBER 22, 2020

It was engineered with the intention of improving deep-lung delivery of Treprostinil in PAH patients by means of a dry powder inhaler. Both POMC deficiency obesity and LEPR deficiency obesity are ultra-rare genetic disorders. The drug is an investigational melanocortin-4 receptor (MC4R) agonist. with LEPR deficiency obesity.

Licensing 52

Licensing Licensing Drugs Gene 52

The Pharma Data

DECEMBER 9, 2020

Overland management plans to execute on its strategy to form partnerships with biotechnology companies seeking to expand the development and commercialization of their innovative therapeutic programs and cutting-edge technology platforms. . Amolyt Pharma – France-based Amolyt Pharma and PeptiDream, Inc.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

OCTOBER 15, 2020

Sabbagh will be responsible for expanding Inozyme’s proprietary pipeline by identifying and developing new therapeutics for monogenic and non-genetic diseases of abnormal mineralization. Nielsen, the primary inventor of peptide nucleic acid (PNA) technology, brings extensive experience in genetic medicine to the company.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

The Pharma Data

JANUARY 18, 2021

oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T We would like to thank the investigators and the clinical teams for their support and look forward to treating the first patients with this first Invir.IO

Trials 40

Trials Antibody Engineer Clinical Trials 40

The Pharma Data

JANUARY 24, 2021

At Elasmogen we have been able to capture, using the latest protein and genetic engineering techniques, the immune system of 10,000 shark equivalents in a test-tube. We then screened these for VNAR binders that block viral infection, and are delighted with the outcomes.”

Antibody 40

Antibody Protein Research Genetic Engineering 40

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

APRIL 1, 2021

Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Kite is engaged in the development of innovative cancer immunotherapies. Tecartus Indication. Source link:[link].

Manufacturing 52

Manufacturing Vaccination Vaccine Development 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

XTalks

DECEMBER 24, 2020

However, for virologists like Lori Frappier, PhD, professor in the department of molecular genetics at the University of Toronto, the outbreak of SARS-CoV-2 was less of a surprise and more of an inevitability. Omer maintains that the solution to this challenge is something that’s already in practice by developers of the mRNA vaccines.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

JANUARY 6, 2025

As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas. While these therapies span all stages of clinical development, they are particularly concentrated in earlier phases, indicating strong future growth. percent from 2022 to 2030.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

Roots Analysis

JANUARY 27, 2025

The company will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for drug substances and drug products, from preclinical to clinical development and commercial production.

Marketing 40

Marketing Manufacturing Production Development 40